Public policy discussions on drug policy often revolve around two opposing views: prohibition and decriminalization. Supporters of both approaches present strong arguments, but they frequently neglect an essential component for success—a system that can handle the increasing demand for addiction treatment and recovery services.
Examining Prohibitionist Concerns
Prohibition advocates highlight the severe risks associated with current drugs, which have become more lethal and addictive than in the past. Synthetic opioids, such as fentanyl, are over 50 times more potent than heroin and have contributed to more than 55,000 overdose deaths in the past year, based on Centers for Disease Control and Prevention provisional data. These dangerous drugs necessitate stringent regulation to safeguard public health.
Analyzing Drug Reform Advocates
Advocates for drug reform criticize the ineffectiveness of the long-standing “war on drugs” in reducing drug trafficking, consumption, and overdose deaths. They propose a fresh approach based on evidence, health, equity, and human rights. Despite over five decades of prohibition, drugs have become cheaper, more potent, and more accessible, despite substantial investment in enforcement efforts. Reform advocates emphasize treating illicit drugs primarily as a public health issue.
The Treatment Infrastructure Challenge
Both prohibition and reform approaches encounter the same obstacle: inadequate treatment infrastructure. History shows that increased regulation can lead to unintended outcomes. For instance, in 2005, the U.S. government implemented strict controls on ephedrine and pseudoephedrine sales to disrupt methamphetamine production, but the crackdown unintentionally shifted production to Mexico, benefiting powerful trafficking organizations. Similarly, as doctors reduced opioid prescriptions, many patients turned to heroin and fentanyl for relief, illustrating that restricting supply without improving treatment access merely shifts demand.
With decriminalization efforts, like Oregon’s Measure 110, insufficiencies in treatment programs contributed to the law’s shortcomings. Measure 110 eliminated criminal penalties for small quantities of illicit drugs, replacing them with a $100 fine that would be waived if individuals sought a health assessment. However, over 95 percent ignored the fine, and less than 1 percent completed the assessment. Oregon was ill-prepared to support those needing treatment.
Building a Better Treatment System
The solution lies in strengthening the nation’s treatment and recovery system, starting with two key areas: personnel and facilities. There’s a significant shortage of professionals in the drug treatment and recovery sector, from addiction counselors to healthcare providers. By 2025, over 40 percent of the U.S. population resided in areas lacking sufficient mental health professionals. This shortage is more pronounced in rural areas and prisons, where substance use and overdose rates are high.
Investing in the behavioral health workforce is crucial. Efforts should focus on enhancing career prospects in treatment through competitive pay, expedited education and licensing processes, stable funding, and improved peer support systems to combat burnout.
The U.S. faces a severe shortage of treatment facilities. Inpatient detox beds, residential treatment centers, and outpatient clinics are scarce. Nearly 80 percent of counties lack opioid treatment programs, the only legal source for methadone to treat opioid use disorder. Wyoming, for example, has none.
Addressing the physical infrastructure involves rapidly expanding treatment capacity, bringing services into underserved communities, and creating safe, accessible locations for immediate care and long-term recovery. These investments are essential to transforming the U.S. drug treatment and recovery system.
In summary, policymakers, prohibitionists, and reformers have often ignored critical elements of the care continuum, leaving many with substance use disorders without adequate support. Regardless of the approach favored, expanding these services is vital for effective drug policy and saving lives. Building this infrastructure is crucial; it serves as the foundation for successful drug policy.
Jim Crotty, the former deputy chief of staff for the U.S. Drug Enforcement Administration, is also an adjunct professor at American University’s School of Public Affairs and a member of the Advisory Board for United Against Fentanyl and End Overdose.
Copyright 2026 Nexstar Media Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Leave a Reply